1. Home
  2. Press release
Oct 06, 2022 20:16 JST

Source: AIM Vaccine Co., Ltd.

AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK

HONG KONG, Oct 06, 2022 - (ACN Newswire) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today, with a board lot of 200 H shares each. The debut of AIM Vaccine's stock price was very outstanding on 6 October. The share price closed at HK$16.66, up 3.09%.

Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited and Macquarie Capital Limited are the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. BOCI Asia Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, and Tiger Brokers (HK) Global Limited are the Joint Bookrunners and Joint Lead Managers. ICBC International Capital Limited is Joint Bookrunner, ICBC International Securities Limited and Livermore Holdings Limited are the Joint Lead Managers.

The Company said that the listing of AIM Vaccine in Hong Kong marks a key milestone and unfolds a new chapter in the Company's development. Looking ahead, AIM Vaccine will continue to strive to access to quality industry resources to expand and optimize its business. The Company will keep abreast of the most advanced platform technologies and innovation trends, accelerating the development of vaccine candidates and continuing to enrich its product portfolio, solidifying and expanding market leadership by increasing sales and marketing efforts for approved vaccine products and commercializing new products, thereby realizing its mission to "develop and manufacture top quality vaccines to safeguard the health of the world", becoming a world-class vaccine company in the global vaccine market and creating greater value for shareholders.


Source: AIM Vaccine Co., Ltd.
Sectors: BioTech, Healthcare & Pharm

Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Release


Honda Makes Gachaco a Consolidated Subsidiary by Subscribing to New Shares of Gachaco Issued Through Third-party Allotment

Apr 01, 2026 22:09 JST

DENSO Hosted "DENSO DIALOG DAY 2026", Delivers Mid-Term Management Plan "CORE 2030"
Apr 01, 2026 21:54 JST

MHI President Eisaku Ito Offers Words of Encouragement to New Employees at the Company's 2026 Welcoming Ceremony
Apr 01, 2026 13:35 JST

MHI Completes the Transfer Procedures for its Domestic Onshore Wind Power Business
Apr 01, 2026 13:26 JST

Toyota Motor Corporation aims to join Daimler Truck and Volvo Group as equal shareholder in the fuel cell joint venture cellcentric
Mar 31, 2026 23:39 JST

Honda Announces the Establishment of PathAhead Co., Ltd., a Startup Originated from IGNITION, a Honda New Business Creation Program
Mar 31, 2026 21:58 JST

Hitachi Digital Services Strengthens OT-IT Integration with Manufacturing Operations Management Platform
Mar 31, 2026 19:14 JST

Fujitsu and Osaka University of Health and Sport Sciences partner to innovate sports performance with skeleton recognition AI
Mar 31, 2026 17:42 JST

DOCOMO and SK Telecom Publish White Paper on Requirements for Advancing vRAN and AI-RAN in Mobile Networks
Mar 31, 2026 11:00 JST

NEC Supports Ooredoo Algeria in Modernizing Enterprise Network Security with high-performance next-generation firewalls (NGFW)
Mar 31, 2026 10:50 JST

MOL and Hitachi Launch Initiative to Convert Used Ships into Floating Data Centers
Mar 30, 2026 19:21 JST

Resona Holdings, BrainPad, and Fujitsu sign basic agreement for collaboration to transform financial operations with data and AI and advance next-generation data utilization
Mar 30, 2026 15:55 JST

MHI Innovative Combustion Dynamics Laboratory is Established at Kyoto University with the Aim of Developing and Socially Implementing World-Leading Technology
Mar 30, 2026 12:53 JST

Fujitsu launches generative AI service that analyzes source code and automatically generates design documents
Mar 30, 2026 10:41 JST

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Mar 27, 2026 20:14 JST

Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility
Mar 27, 2026 19:44 JST

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Mar 27, 2026 18:19 JST

New "L00 Series" Train for the Seibu Railway's Yamaguchi Line Begins Commercial Operation
Mar 27, 2026 16:51 JST

Fujitsu develops high-sensitivity, high-resolution infrared sensor to expand monitoring capabilities in defense and disaster prevention
Mar 27, 2026 14:07 JST

Sharp Develops Long-Range Video Monitoring Technology
Mar 26, 2026 22:39 JST
 More Latest Release >>

Related Release

AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
October 05 2022 18:55 JST
 
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
September 23 2022 17:06 JST
 
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
January 12 2022 10:26 JST
 
More Press release >>